SLC5A2 and chronic kidney disease: SGLT2 inhibition cause volume contraction, decreased blood pressure, and reduces glomerular pressure (Lytvyn et al. 2017). SGLT2 inhibition-mediated natriuresis is likely a major factor leading to cardiorenal protective effects observed with empagliflozin and canagliflozin, which appear to extend across CKD stages (Petrykiv et al. 2017).